Search clinical trials for: ACT001 Pembrolizumab

Total 2552 results

Accendatech USA Inc.
Avance Clinical Pty Ltd.; C3 Research Associates

Recruiting

A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme

Recurrent Glioblastoma Multiforme(GBM)

United States
Abyss Ingredients
Eurofins

Recruiting

Efficacy of Marine By-product Hydrolysate on the Reduction of Atopic Dermatitis Symptoms

Eczema | Atopic Dermatitis

Spain
National Cancer Institute (NCI)

Completed

Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer

Medullary Thyroid Cancer (MTC)

United States
AiViva BioPharma, Inc.

Completed

A Safety and Efficacy Study to Evaluate Wound Healing

Wound Heal

United States
Avotres Inc.

Active, not recruiting

Safety, Tolerability and Potential Efficacy of AVT001 in Patients With Type 1 Diabetes

Type 1 Diabetes Mellitus

United States
Achilles Therapeutics UK Limited

Recruiting

ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC

Advanced Non Small Cell Lung Cancer

United States, Spain, Germany, France, United Kingdom
Promius Pharma, LLC

Completed

ACT01 in Combination With Comp01-04 in Patients With Actinic Keratosis

Actinic Keratosis

United States
Emory University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy

Plasma Cell Myeloma

United States
Emory University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; National Institutes...

Active, not recruiting

Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer

Recurrent Skin Carcinoma | Skin Squamous Cell Carcinoma

United States
Medivir
Merck Sharp & Dohme LLC

Terminated

Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors

Solid Tumors

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer

Recurrent Ovarian Carcinoma | Malignant Ovarian Clear Cell Tumor

United States, Puerto Rico
Basilea Pharmaceutica

Completed

Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects

Fungal Infection

Netherlands
University of Washington
National Cancer Institute (NCI)

Terminated

Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia

B Acute Lymphoblastic Leukemia | Recurrent Acute Lymphoblastic Leukemia | Minimal Residual Disease | T Acute Lymphoblastic Leukemia

United States
National Cancer Institute (NCI)

Completed

Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome

Recurrent Mycosis Fungoides and Sezary Syndrome | Refractory Mycosis Fungoides and Sezary Syndrome | Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7 | Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7 | Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7 | Stage IIIA Mycosis... and other conditions

United States
AiViva BioPharma, Inc.

Completed

Safety and Efficacy of AIV001 on Scar Formation and Keloid Recurrence Following Keloidectomy

Keloid

United States
Sinocelltech Ltd.

Unknown

The Safety and Efficacy of SCTA01 Against COVID-19 in Patients Admitted to High Dependence or Intensive Care

Covid19
Emory University
National Cancer Institute (NCI); National Institutes of Health (NIH); Exelixis

Active, not recruiting

Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer

Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Stage IV Hypopharyngeal Squamous Cell Carcinoma... and other conditions

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Terminated

Pembrolizumab in Treating Patients With Advanced Uveal Melanoma

Stage IV Uveal Melanoma | Stage IIIA Uveal Melanoma | Stage IIIB Uveal Melanoma | Stage IIIC Uveal Melanoma

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Recruiting

Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability

BRCA1 Gene Mutation | BRCA2 Gene Mutation | Recurrent Ovarian Carcinoma | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC... and other conditions

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

MK-3475 as Maintenance Therapy in Extensive Stage SCLC

Extensive Stage Small Cell Lung Carcinoma

United States
Regeneron Pharmaceuticals

Not yet recruiting

A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

Melanoma
Mirati Therapeutics Inc.

Recruiting

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Advanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer

United States, Korea, Republic of, Italy, Spain, Czechia, Hungary, Netherlands, Canada, Australia, Austria, Belgium, Germany, Ireland, Israel, Poland, United Kingdom, Taiwan, Portugal
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer

Pancreatic Ductal Adenocarcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Homologous Recombination Deficiency | Stage IIA Pancreatic Cancer AJCC v8 | Stage IIB Pancreatic Cancer AJCC v8 | ATM Gene Mutation | Deleterious BRCA1 Gene... and other conditions
Coegin Pharma AB
Bispebjerg Hospital; Studies&Me

Active, not recruiting

Phase I/IIa Trial to Evaluate AVX001 Gel in Doses of 1% or 3% Compared With Vehicle Over Four Weeks of Field-directed Treatment Period in Adult Subjects With AK (COAKS)

Actinic Keratoses

Denmark
QIAGEN Gaithersburg, Inc

Completed

Evaluation of the 4th Generation QuantiFERON-TB Test (QFT-Plus) for the Detection of Tuberculosis Infection

Tuberculosis

United States
QIAGEN Gaithersburg, Inc

Completed

Evaluation of the QuantiFERON-TB Test.

Tuberculosis

United States
ImCheck Therapeutics
ILife Consulting; Exystat

Recruiting

Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid Tumors (EVICTION-2)

Solid Tumor, Adult

France
Basilea Pharmaceutica

Completed

Safety, Pharmacokinetics, Bioavailability, Food Effect, Drug-Drug Interaction Study of APX001 Administered Orally

Fungal Infection

Netherlands
Shanghai PerHum Therapeutics Co., Ltd.
Shanghai Public Health Clinical Center

Active, not recruiting

Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma

Renal Cell Carcinoma

China
Jonsson Comprehensive Cancer Center
Merck Sharp & Dohme LLC

Completed

Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Stage IV Non-Small Cell Lung Cancer

United States
Northwestern University
National Cancer Institute (NCI)

Terminated

Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer

Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8

United States
Shanghai Vinnerna Biosciences Co., Ltd.

Withdrawn

Evaluate the Pharmacokinetics, Safety and Tolerability of JT001 Tablets

Healthy Subjects

Australia
Pfizer

Completed

An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris (APEX)

Candidemia | Candida Infection | Invasive Candidiases

South Africa
AiViva BioPharma, Inc.

Withdrawn

A Safety and Efficacy Study to Evaluate Rosacea

Papulopustular Rosacea

United States
Novartis Pharmaceuticals

Completed

Pharmacokinetics Study of Asciminib in Subjects With Impaired Renal Function Compared to Matched Healthy Volunteers

Renal Impairment

Germany, Bulgaria
Pinteon Therapeutics, Inc

Completed

Safety and Tolerability of PNT001 in Healthy Adults

Healthy

United States
Alfred Chung, MD
Merck Sharp & Dohme LLC

Terminated

Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies

Multiple Myeloma | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

United States
Allakos Inc.

Completed

Study to Evaluate Multiple Doses in Patients With Nasal Polyposis

Nasal Polyposis

Belgium, United States, Germany, Netherlands, Spain, United Kingdom
Pearl Therapeutics, Inc.

Completed

Study to Evaluate Single Inhaled Doses of PT001, PT003, PT005 and PT001 Plus PT005 in Healthy Subjects

Healthy Volunteers

Australia
Baliopharm Pty Ltd

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Atrosimab (ATM001) in Healthy Volunteers

Healthy Volunteers

Australia
DNAtrix, Inc.
Merck Sharp & Dohme LLC

Completed

Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects (CAPTIVE)

Nervous System Diseases | Glioma | Glioblastoma | Neuroectodermal Tumors | Brain Cancer | Gliosarcoma | Brain Neoplasm | Malignant Brain Tumor | Neoplasm, Neuroepithelial | Neoplasm by Histologic Type | Neoplasm, Nerve Tissue

United States, Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer

Stage III Thymoma AJCC v8 | Stage IIIA Thymoma AJCC v8 | Stage IIIB Thymoma AJCC v8 | Stage IV Thymoma AJCC v8 | Stage IVA Thymoma AJCC v8 | Stage IVB Thymoma AJCC v8 | Unresectable Thymic Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy

Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast Cancer AJCC v8 | Prognostic Stage IIIC Breast Cancer AJCC v8 | Breast Inflammatory Carcinoma

United States
IFOM ETS - The AIRC Institute of Molecular Oncology

Active, not recruiting

Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status (ARETHUSA)

Colorectal Neoplasms | Microsatellite Instability

Italy
AiViva BioPharma, Inc.

Completed

Safety and Efficacy of AIV001 on Low Risk Basal Cell Carcinoma

Nodular Basal Cell Carcinoma | Superficial Basal Cell Carcinoma

United States
Talaris Therapeutics Inc.

Withdrawn

A Safety and Efficacy Study of FCR001 in Adults With Rapidly Progressive Diffuse Cutaneous Systemic Sclerosis (FREEDOM-3)

Diffuse Cutaneous Systemic Sclerosis

United States
Shanghai Zhongshan Hospital
Transcenta Holding Limited

Completed

TST001 in Patients With CLDN18.2 Positive Previously Treated Advanced Biliary Tract Cancer

Biliary Tract Neoplasms

China
Blue Note Therapeutics
Durham VA Health Care System

Terminated

BNT001 Digital Therapeutic Feasibility Pilot Study

Cancer

United States
Novartis Pharmaceuticals

Completed

A Trial to Evaluate the Pharmacokinetics of ABL001 in Healthy and Hepatic Impaired Subjects

Hepatic Impairment

United States
QIAGEN Gaithersburg, Inc

Completed

Evaluation of the QuantiFERON-TB Test.

Tuberculosis

United States

Search clinical trials for: ACT001 Pembrolizumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ethiopia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations